Weight loss drugs like Ozempic deliver more health benefits than expected.

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

After a series of small health issues, Becky's condition quickly deteriorated. When she rang the GP they told her to come in ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

G LP-1 drugs containing semaglutide (the active ingredient in Ozempic and Wegovy) have exploded in popularity for their ...